- |||||||||| 2aG4 / Avid Bioservices
Journal: Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface. (Pubmed Central) - May 29, 2020 Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4)...Treated tumors showed reduced levels of both MYCN and PA2G4. Our findings demonstrate a critical role for PA2G4 as cofactor in MYCN-driven neuroblastoma and highlight competitive inhibition of the PA2G4-MYCN protein binding as a novel therapeutic strategy in the disease.
- |||||||||| Tarvacin (bavituximab) / Oncologie, 2aG4 / Peregrine
Activation of toll-like receptors via PS-targeting monoclonal antibodies (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_703; Overall these data support that one mechanism of innate immune activation induced by PS-targeting mAbs is through TLR2 stimulation on myeloid cells. Future studies are focused on validating these results in vivo using Tlr-deficient and b2gp1-deficient mice.
|